Prostate Radiotherapy May Be Linked to Late GU Toxicities
Recent findings suggest potential links between prostate radiotherapy and late genitourinary toxicities, warranting further exploration.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
Breaking news: The Lorigerlimab trial has been put on a partial clinical hold by the FDA due to severe safety incidents, including one fatality directly linked to the treatment.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
There are substantial improvements in managing malignant melanoma with the use of immune-checkpoint inhibitors, presenting new hope for patients.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
Big development: The FDA has granted fast track designation to SRN-101, a promising solution for the treatment of recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Early phase 1 trial results show encouraging signs for a novel small molecule, KTX-1001, in patients with pre-treated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A 2025 study sheds light on the quality of life outcomes in oropharyngeal cancer patients undergoing proton therapy, with a focus on immune preservation and minimizing long-term adverse effects.
